Home
InvaGen Pharmaceuticals

InvaGen Pharmaceuticals Market Share Analysis for May 2026

built on the foundation of caring for life, cipla ensures access to quality & affordable medicines through 1500+ products across various therapeutic categories.

Industry: N/A

Domaininvagen.com

Year Founded2003

Employees501 - 1000

Annual Revenue$200M - $500M

InvaGen Pharmaceuticals

InvaGen Pharmaceuticals (including company regionals)

invagen.com

See more website traffic and engagement information

InvaGen Pharmaceuticals Revenue up to May 2026 is 200M - 500M

revenue generated by InvaGen Pharmaceuticals top domains

InvaGen Pharmaceuticals top domains revenue over 3 years

Revenue for InvaGen Pharmaceuticals top domains

invagen.com200M - 500M

See more with Sales Intelligence

Total visits to InvaGen Pharmaceuticals's top domains

Understand InvaGen Pharmaceuticals market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in InvaGen Pharmaceuticals's top domains

Analyze InvaGen Pharmaceuticals engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on InvaGen Pharmaceuticals's top domains

See how InvaGen Pharmaceuticals keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

InvaGen Pharmaceuticals top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by InvaGen Pharmaceuticals

These are the website technologies, by industry, used by InvaGen Pharmaceuticals top domains

Content Management System (3)

WordPress

Advertising (1)

Awin

Conversion & Analytics (1)

Google Analytics

Email Services (1)

G Suite

More Technologies

4

See all

News & Signals from InvaGen Pharmaceuticals

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCipla acquired Invagen for $550M on Jan 1st '15.Cipla entered the US market in a big way with the strategic acquisitions of two generic companies, InvaGen Pharma and Exelan Pharma, for $550 million in 2015.

NewsInvagen invests into assets: product under development and related assets in the amount of $12.5M.Pharma major Cipla ‘ s subsidiary InvaGen Pharmaceuticals Inc is acquiring US-based specialty business firm Avenue Therapeutics for up to $215 million while Aurobindo Pharma Ltd agreed to buy a product under development and related assets from Australia-based Advent Pharmaceuticals Pty. Ltd for $12.5 million in an all-cash deal.

NewsInvagen acquired Avenue Therapeutics for $215M on Nov 1st '18.New Delhi, Nov 13 () Drug major Cipla Tuesday said its subsidiary InvaGen Pharmaceuticals Inc has entered into definitive agreements to acquire US-based speciality business firm Avenue Therapeutics for up to USD 215 million (around Rs 1,560 crore).